Evaluation of Serum Cathepsin B and D in Relation to Clinicopathological Staging of Colorectal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2005 Jul 15

PMID 16015694

Citations 8

Authors

Elzbieta Skrzydlewska

Mariola Sulkowska

Andrzej Wincewicz

Mariusz Koda

Stanislaw Sulkowski

Affiliations

Soon will be listed here.

Abstract

Aim: Proteolytic degradation of the extracellular matrix facilitates cancer invasion and promotes metastasis. The study aims at evaluation of preoperative and postoperative serum cathepsins B and D levels in correlation with selected anatomoclinical features of colorectal cancer.

Methods: Blood samples were collected from 63 colorectal cancer patients before curative operation of the tumor 10 d later. Blood that was obtained from 20 healthy volunteers, served as a control. The activity of cathepsin B was measured with Bz-DL-arginine-pNA as a substrate at pH 6.0, while cathepsin D activity was determined with urea-denatured hemoglobin (pH 4.0).

Results: The preoperative and postoperative activities of cathepsin B were significantly (P<0.00001) lower in serum of colorectal cancer patients than in control group. However, postoperative values of this protease were significantly increased in comparison with preoperative ones (P = 0.031). Activity of cathepsin D appeared to be significantly higher in colorectal cancer sera (P<0.00001) compared with controls. No statistically significant differences between preoperative and postoperative activity of cathepsin D were noted (P = 0.09). We revealed a strong linkage of cathepsins' levels with lymph node status and pT stage of colorectal cancer.

Conclusion: Blood serum activities of cathepsin B and D depend on the time of sampling, tumor size and lymph node involvement. Significantly, increased activity of cathepsin D could indicate a malignant condition of the large intestine. In our work, the serum postoperative decrease of cathepsin B activity appears as an obvious concomitant of local lymph node metastasis-the well-known clinicopathological feature of poor prognosis.

Citing Articles

Association of Serum Proteases and Acute Phase Factors Levels with Survival Outcomes in Patients with Colorectal Cancer.

Sebzda T, Karwacki J, Cichon A, Modrzejewska K, Heimrath J, Latka M Cancers (Basel). 2024; 16(13).

PMID: 39001534 PMC: 11240471. DOI: 10.3390/cancers16132471.

Diagnostic usefulness of selected proteases and acute phase factors in patients with colorectal adenocarcinoma.

Sebzda T, Gnus J, Dziadkowiec B, Latka M, Gburek J World J Gastroenterol. 2021; 27(39):6673-6688.

PMID: 34754160 PMC: 8554409. DOI: 10.3748/wjg.v27.i39.6673.

Role of lysosomes in physiological activities, diseases, and therapy.

Zhang Z, Yue P, Lu T, Wang Y, Wei Y, Wei X J Hematol Oncol. 2021; 14(1):79.

PMID: 33990205 PMC: 8120021. DOI: 10.1186/s13045-021-01087-1.

Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Chen W, Chen J, Jiao B, Lin W, Wu Y, Liu L J Virol. 2012; 86(24):13533-41.

PMID: 23035214 PMC: 3503111. DOI: 10.1128/JVI.02095-12.

The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Tsume Y, Amidon G Molecules. 2012; 17(4):3672-89.

PMID: 22450679 PMC: 3565751. DOI: 10.3390/molecules17043672.

References

Williams S, Gotley D, Antalis T . Human trypsinogen in colorectal cancer. Int J Cancer. 2001; 93(1):67-73. DOI: 10.1002/ijc.1304. View

Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G . Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett. 2004; 205(1):97-106. DOI: 10.1016/j.canlet.2003.09.033. View

Brouillet J, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J . Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer. 1997; 79(11):2132-6. View

Buck M, Karustis D, Day N, Honn K, Sloane B . Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 1992; 282 ( Pt 1):273-8. PMC: 1130919. DOI: 10.1042/bj2820273. View

Sis B, Sagol O, Kupelioglu A, Sokmen S, Terzi C, Fuzun M . Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract. 2004; 200(5):379-87. DOI: 10.1016/j.prp.2004.02.012. View

Ducroc R, Bontemps C, Marazova K, Devaud H, Darmoul D, Laburthe M . Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. Life Sci. 2002; 70(12):1359-67. DOI: 10.1016/s0024-3205(01)01519-3. View

Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M . Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol. 2001; 153(5):999-1010. PMC: 2174340. DOI: 10.1083/jcb.153.5.999. View

Matsuo K, Kobayashi I, Tsukuba T, Kiyoshima T, Ishibashi Y, Miyoshi A . Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol. 1996; 27(2):184-90. DOI: 10.1016/s0046-8177(96)90373-1. View

Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, Sloane B . Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 1994; 145(2):301-9. PMC: 1887383. View

10.

Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D . MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res. 1991; 194(2):252-9. DOI: 10.1016/0014-4827(91)90362-x. View

11.

Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J . Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett. 1998; 130(1-2):49-56. DOI: 10.1016/s0304-3835(98)00114-1. View

12.

Kostoulas G, Lang A, Nagase H, Baici A . Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 1999; 455(3):286-90. DOI: 10.1016/s0014-5793(99)00897-2. View

13.

Ugarova T, Ljubimov A, Deng L, Plow E . Proteolysis regulates exposure of the IIICS-1 adhesive sequence in plasma fibronectin. Biochemistry. 1996; 35(33):10913-21. DOI: 10.1021/bi960717s. View

14.

van der Stappen J, Williams A, Maciewicz R, Paraskeva C . Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer. 1996; 67(4):547-54. DOI: 10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4. View

15.

Glondu M, Coopman P, Laurent-Matha V, Garcia M, ROCHEFORT H, Liaudet-Coopman E . A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene. 2001; 20(47):6920-9. DOI: 10.1038/sj.onc.1204843. View

16.

Lah T, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R . Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Hum Pathol. 2000; 31(2):149-60. DOI: 10.1016/s0046-8177(00)80214-2. View

17.

Kos J, Nielsen H, Krasovec M, Christensen I, Cimerman N, Stephens R . Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res. 1998; 4(6):1511-6. View

18.

Teich N, Bodeker H, Keim V . Cathepsin B cleavage of the trypsinogen activation peptide. BMC Gastroenterol. 2002; 2:16. PMC: 117221. DOI: 10.1186/1471-230x-2-16. View

19.

Hirtenlehner K, Pec M, Kubista E, Singer C . Influences of stroma-derived growth factors on the cytokine expression pattern of human breast cancer cell lines. Arch Gynecol Obstet. 2002; 266(2):108-13. DOI: 10.1007/s00404-001-0278-z. View

20.

Ikeda Y, Ikata T, Mishiro T, Nakano S, Ikebe M, Yasuoka S . Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J Med Invest. 2000; 47(1-2):61-75. View